ATS releases guidelines on the management of pulmonary hypertension of sickle cell disease

March 15, 2014

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

"With the development of new treatments, many with are now surviving long enough to develop pulmonary hypertension, with an estimated prevalence of 6 to 11 percent," said Elizabeth S. Klings, MD, associate professor of medicine at the Boston University School of Medicine and chair of the committee that produced the guidelines. "Although pulmonary hypertension and elevated tricuspid jet velocity (TRV, an indicator of pulmonary hypertension measured by echocardiography) are both associated with an increased , there is currently no standardized approach for identifying and managing these patients."

The guidelines appear in the March 15th issue of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Guideline recommendations include:

  • Mortality risk can be accurately determined noninvasively by measurement of the TRV with Doppler echocardiography or by measurement of serum N-terminal pro–brain natriuretic peptide (NT-pro-BNP) levels and can be determined invasively by direct hemodynamic measurements via right heart catheterization (RHC).
  • An increased risk for mortality is defined as a TRV ≥ 2.5 m/second, an NT-pro-BNP level ≥ 160 pg/ml, or RHC-confirmed pulmonary hypertension.
  • Patients found to have an increased mortality risk should be treated with hydroxyurea. Patients who do not respond to or are not candidates for hydroxyurea treatment can be considered for chronic transfusion therapy.
  • In patients with RHC-confirmed pulmonary hypertension, venous thromboembolism, and no additional risk factors for hemorrhage, indefinite anticoagulant therapy rather than a limited duration of therapy should be used.
  • Patients with elevated TRV alone or elevated NT-pro-BNP alone should not be treated with targeted therapies, including prostanoid, endothelin receptor antagonist, and phosphodiesterase-5 inhibitor therapy
  • Most patients with RHC-confirmed pulmonary hypertension should not be treated with targeted therapy
  • In select patents with RHC-confirmed marked elevation of pulmonary vascular resistance, normal pulmonary capillary wedge pressure, and related symptoms, a trial of either a prostanoid or an endothelin receptor antagonist may be performed.
  • Patients with RHC-confirmed marked elevation of pulmonary vascular resistance, normal pulmonary capillary wedge pressure, and related symptoms should not receive phosphodiesterase-5 inhibitor therapy as first-line treatment.

"As our understanding of sickle cell disease develops, so will our ability to detect disease earlier and to tailor treatment approaches. We need to continue our research efforts into this disease and its management to understand what the optimal treatment regimen for these patients is. Most of our current recommendations are limited by a lack of large-scale clinical trials in this population." said Dr. Klings. "Management of patients with sickle cell disease with an for mortality and will ultimately be a collaborative effort including adult and pediatric pulmonologists, cardiologists, and hematologists."

Explore further: Macitentan cuts morbidity, death in pulmonary arterial HTN

Related Stories

Macitentan cuts morbidity, death in pulmonary arterial HTN

August 29, 2013
(HealthDay)—For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. ...

By zooming in on arteries, researcher gets to the root of pulmonary hypertension

February 27, 2014
You might think building muscle is a good thing, but that's often not so in the case of blood vessels in adults. In fact, excess smooth muscle is a root problem in many vascular diseases, as it causes arteries to constrict ...

Tricuspid regurgitant jet velocity up in childhood cancer survivors

January 18, 2013
(HealthDay)—About one-quarter of adult survivors of childhood cancer who received chest-directed radiation therapy (RT) have increased tricuspid regurgitant jet velocity (TRV), according to research published online Jan. ...

Biomarker identified in systemic sclerosis predicts progression

December 19, 2013
(HealthDay)—Patients with systemic sclerosis have elevated levels of CXCL4, which predicts disease risk and progression, according to a study published online Dec. 18 in the New England Journal of Medicine.

Discovery sheds light on how changes in lungs can hurt the heart

November 11, 2013
A team of UW-Madison researchers has discovered important biomechanical changes in human arteries that could increase understanding of how pulmonary hypertension leads to heart failure.

Pulmonary hypertension combination therapy may lead to greater disease burden

October 22, 2012
Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding ...

Recommended for you

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.